Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,991,843
  • Shares Outstanding, K 303,846
  • Annual Sales, $ 853,830 K
  • Annual Income, $ 690,070 K
  • 60-Month Beta 1.74
  • Price/Sales 6.43
  • Price/Cash Flow 13.02
  • Price/Book 3.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.17
  • Number of Estimates 6
  • High Estimate 0.25
  • Low Estimate 0.12
  • Prior Year 0.37
  • Growth Rate Est. (year over year) -54.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.69 +17.22%
on 01/06/20
20.76 -5.73%
on 01/16/20
+0.77 (+4.10%)
since 12/23/19
3-Month
15.02 +30.29%
on 11/06/19
20.76 -5.73%
on 01/16/20
+2.87 (+17.19%)
since 10/23/19
52-Week
15.02 +30.29%
on 11/06/19
25.31 -22.68%
on 03/18/19
-2.55 (-11.53%)
since 01/23/19

Most Recent Stories

More News
GILD or EXEL: Which Is the Better Value Stock Right Now?

GILD vs. EXEL: Which Stock Is the Better Value Option?

GILD : 63.94 (+0.80%)
EXEL : 19.57 (-0.76%)
SmarTrend Watching for Potential Pullback in Shares of Exelixis Inc After 5.34% Gain

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $19.70 to a high of $20.74. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high of $19.72...

EXEL : 19.57 (-0.76%)
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

EXEL : 19.57 (-0.76%)
Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

--- Presentation and webcast at 2020 J.P. Morgan Healthcare Conference on Tuesday, January 14th at 4:30 PM Pacific Time -

JPM : 136.54 (-0.10%)
EXEL : 19.57 (-0.76%)
Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study

Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.

MRK : 88.56 (-1.22%)
RHHBY : 42.3900 (-0.45%)
BAYRY : 21.5900 (+4.05%)
EXEL : 19.57 (-0.76%)
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

A low-key week for the biotech sector, with a few pipeline and regulatory updates.

LIFE : 5.92 (-1.82%)
INCY : 78.24 (-0.31%)
EXEL : 19.57 (-0.76%)
APLS : 42.29 (-0.42%)
Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the 38th Annual J.P. Morgan Healthcare...

JPM : 136.54 (-0.10%)
EXEL : 19.57 (-0.76%)
Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

--- Initial data to be presented on February 13 at the 2020 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO GU 2020) in San Francisco, CA -

EXEL : 19.57 (-0.76%)
After Yesterday's Rally of 1.09% Shares Could Potentially Pullback

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $18.70 to a high of $18.97. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $18.89...

EXEL : 19.57 (-0.76%)
Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

--- Collaboration based on data from phase 1b COSMIC-021 trial -

EXEL : 19.57 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade EXEL with:

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 20.14
1st Resistance Point 19.85
Last Price 19.57
1st Support Level 19.18
2nd Support Level 18.80

See More

52-Week High 25.31
Fibonacci 61.8% 21.38
Fibonacci 50% 20.17
Last Price 19.57
Fibonacci 38.2% 18.95
52-Week Low 15.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar